TWiV 1048: Clinical update with Dr. Daniel Griffin

In his weekly clinical update, Dr. Griffin discusses a molnupiravir-associated mutational signature in global SARS-CoV-2 genomes, inhaled fluticasone furoate for outpatient treatment of COVID-19, optimal duration of systemic corticosteroids in COVID-19 treatment, early antibody treatment, inflammation, and risk of post-COVID conditions, autonomic dysregulation in long-term patients suffering from post-COVID-19 syndrome assessed by heart rate variability, and multiorgan MRI findings after hospitalization with COVID-19 in the UK. Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode Molnupiravir-associated mutational signature in global SARS-CoV-2 genomes (Nature) Inhaled fluticasone furoate for outpatient treatment of COVID-19 (NEJM) Optimal duration of systemic corticosteroids in COVID-19 treatment (OFID) Distinguishing features of Long COVID identified through immune profiling (Nature) Early antibody treatment, inflammation, and risk of post-COVID conditions (mBIO) Autonomic dysregulation in long-term patients suffering from post COVID-19 syndrome (SR) Multiorgan MRI findings after hospitalization with COVID-19 in the UK (The Lancet) Contribute to our Floating Doctors fundraiser at PWB Letters read on TWiV 1048 Dr. Griffin’s COVID treatment summary (pdf) Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to [email protected]